Skip to content
HowShorted

RHYTHM PHARMACEUTICALS, INC. short interest in 2025

In 2025, RHYTHM PHARMACEUTICALS, INC.'s disclosed short interest ran from 8.87% of shares outstanding on 15 Jan 2025 to 9.29% on 31 Dec 2025, a change of +0.42 percentage points. The year's high was 9.29% on 31 Dec 2025 and its low 7.04% on 15 Aug 2025, averaging 8.00% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.55 days on 14 Feb 2025. Full history: RHYTHM PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for RHYTHM PHARMACEUTICALS, INC. in 2025

2025 in figures

Start of year
8.87% (15 Jan 2025)
End of year
9.29% (31 Dec 2025)
Change
+0.42 pp
High
9.29% (31 Dec 2025)
Low
7.04% (15 Aug 2025)
Average
8.00%
Highest days to cover
13.55 (14 Feb 2025)
SEC filings marked
9

Every report in 2025

RHYTHM PHARMACEUTICALS, INC. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20258.87%9.91results (8-K)
31 Jan 20258.34%10.87
14 Feb 20258.80%13.55
28 Feb 20258.37%9.05results (8-K), 10-K filed
14 Mar 20257.66%8.39
31 Mar 20257.58%8.90
15 Apr 20258.31%4.14
30 Apr 20257.63%7.63
15 May 20257.97%6.9710-Q filed, results (8-K)
30 May 20257.51%9.25
13 Jun 20257.48%8.08
30 Jun 20257.63%8.53
15 Jul 20257.53%3.48
31 Jul 20257.10%8.27
15 Aug 20257.04%7.4510-Q filed, results (8-K)
29 Aug 20257.48%9.80
15 Sep 20257.86%8.57
30 Sep 20258.40%7.83
15 Oct 20258.39%10.56
31 Oct 20257.84%9.24
14 Nov 20258.24%7.0010-Q filed, results (8-K)
28 Nov 20258.27%8.53
15 Dec 20258.36%4.98
31 Dec 20259.29%8.04

See also: RHYTHM PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.